Program
E-3810
Also written as “E3810”, “Lucitanib” and “AL3810”.
Its studies are mostly in Thymoma · Genital Neoplasms, Female · Breast Neoplasms · Small Cell Lung Carcinoma · Carcinoma, Non-Small-Cell Lung, led by 3 companies.
Drug pageE-3810: every studyAll 14 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eisaiits history only | 40 open or running | phase 3since Sep 12, 2005 | Sep 12, 2005 | none ahead |
| Haihe Biopharmaits history only | 40 open or running | phase 3since Jan 16, 2020 | Dec 16, 2016 | none ahead |
| Clovis Oncology | 30 open or running | phase 2since Apr 7, 2014 | Apr 7, 2014 | none ahead |
Also a collaborator on its studies: Bristol-Myers Squibb.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Clovis Oncology only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 7, 2014First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT02109016 · 18 enrolled · United States, France, Germany and more
- Jul 25, 2014Phase 2 study in Breast NeoplasmsNCT02202746 · 178 enrolled · United States
- Jul 19, 2019Phase 2 study in Genital Neoplasms, FemaleNCT04042116 · 227 enrolled · United States, Austria, Belgium and more
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 Clovis Oncology leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04042116Genital Neoplasms, Female · United States, Austria, Belgium and more | 2 | Suspended | Jul 2023 | 227 |
| NCT02202746Breast Neoplasms · United States | 2 | Terminated | Jan 17, 2017 | 178 |
| NCT02109016Carcinoma, Non-Small-Cell Lung · United States, France, Germany and more | 2 | Terminated | Apr 1, 2016 | 18 |
How it is read
Names in the registry
- “E3810”, 8 entries
- “Lucitanib”, 6 entries
- “AL3810”, 4 entries
- “lucitanib 15 mg QD”, 1 entry
- “lucitanib 10 mg QD”, 1 entry
Conditions, from the studies’ own filings
- Thymoma, 1 study
- Genital Neoplasms, Female, 1 study
- Breast Neoplasms, 1 study
- Small Cell Lung Carcinoma, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.